文献速递脊柱关节炎

生物及靶向合成DMARD治疗中难治性银屑病关节炎的患病率与特征:5个北欧注册研究

Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries.
PubMed 文献 · Ann Rheum Dis · 2026-09-05

基于5个北欧生物制剂注册研究,纳入1999至2020年首次启用b/tsDMARD的14362例PsA患者,中位随访6.3年。停用≥2/≥3/≥4种b/tsDMARD者分别占36%/18%/10%;按EULAR框架组件定义,难治性(D2M)患病率分别为2%/3%/3%,真正治疗难治者分别为1.2%/1.2%/0.8%,女性、抑郁及阿片类药物使用随停药次数增加而增多。

要点

  • 多线b/tsDMARD停用在真实世界常见,停用≥2种者达36%。
  • 完全满足D2M组件者约2%–3%,治疗难治者约0.8%–1.2%。
  • 女性、抑郁及阿片使用随b/tsDMARD停药次数增加而更常见。

核心结论

  • 真实世界中多线b/tsDMARD停用常见,但完全符合D2M框架者比例较低(约2%–3%),治疗难治者约0.8%–1.2%。
  • D2M与治疗难治性PsA患者中女性、抑郁及阿片类药物使用比例更高。

研究设计与样本

  • 基于5个北欧生物制剂注册研究的队列研究,随访1999至2020年首次启用b/tsDMARD的PsA患者,共14362例,中位随访6.3年(IQR 2.4–10.7)。
  • 先定义停用≥2、≥3或≥4种b/tsDMARD的三个队列,再依次叠加停药原因、≥2种作用机制停用、患者总体评分≥30 mm、持续疾病活动等组件。

主要发现

  • 停用≥2/≥3/≥4种b/tsDMARD者分别占36%/18%/10%。
  • 叠加全部组件后,D2M患病率分别为2%/3%/3%,对应治疗难治患病率为1.2%/1.2%/0.8%。
  • 女性、抑郁及阿片类药物使用随b/tsDMARD停药次数增加而增多。

关键数值与推荐

  • D2M组件包括:停用≥2/≥3/≥4种b/tsDMARD、停药原因为无效或副作用、停用≥2种不同作用机制、患者总体评分≥30 mm、持续疾病活动(压痛/肿胀关节数≥1、CRP>10 mg/L或DAPSA28>14)。
  • 治疗难治定义为原发/继发b/tsDMARD无效(非副作用/不耐受/禁忌)且存在客观炎症(压痛/肿胀关节数≥1或CRP>10 mg/L)。

临床怎么用

  • registry数据可用于估算D2M与治疗难治性PsA的负担,但需注意EULAR框架组件在注册研究中的可操作性。
  • 对多次更换b/tsDMARD的PsA患者,应关注女性、抑郁及阿片类药物使用等特征并综合管理。

局限性

  • 回顾性设计无法直接验证EULAR定义。
  • 结论需前瞻性研究进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The European Alliance of Associations for Rheumatology (EULAR) recently proposed a framework for 'difficult-to-manage' (D2M) and 'treatment-refractory' disease in psoriatic arthritis (PsA). We explored real-world prevalence and characteristics of patients fulfilling registry-based components inspired by EULAR's framework among patients with PsA initiating biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD). METHODS: Cohort study from 5 Nordic biologics registries with follow-up of patients initiating first b/tsDMARD 1999 to 2020. First (step 1a), 3 cohorts were defined: discontinuation of ≥2, ≥3, or ≥4 b/tsDMARDs, respectively. Additional components were added sequentially to each cohort: (1b) b/tsDMARD-discontinuation reason (inefficacy/side effects); (1c) discontinuation of ≥2 different mechanisms of action (with 1a+1b+1c providing nuanced understanding of switching patterns); (2) problematic signs/symptoms (patient global score ≥ 30 mm); (3) persistent disease activity (tender/swollen joint count ≥1, C-reactive protein [CRP] > 10 mg/L, or Disease Activity index in PSoriatic Arthritis 28-joint counts >14). Treatment-refractory disease required primary/secondary b/tsDMARD inefficacy (not side-effects/intolerability/contraindications), and objective inflammation (tender/swollen joint count ≥ 1, or CRP > 10 mg/L). RESULTS: Among 14,362 patients, discontinuation of ≥2/≥3/≥4 b/tsDMARDs occurred in 36%/18%/10%, respectively, during a median(IQR) follow-up of 6.3 years (2.4-10.7). Applying all components (1a-3), D2M prevalences were 2%/3%/3%, respectively. Corresponding treatment-refractory prevalences were 1.2%/1.2%/0.8%, respectively. Female sex, depression, and opioid use increased with the number of b/tsDMARD discontinuations. CONCLUSIONS: In routine care, multiple b/tsDMARD discontinuations were common. Two percent were D2M, and 1.2% were treatment-refractory, both characterised by a higher prevalence of women, depression, and opioid use. Although our retrospective design did not allow testing of the EULAR definitions, our findings highlight the complexity of D2M and treatment-refractory PsA and underline the need for prospective studies.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nielung LM, Giuseppe DD, Hetland ML, et al. Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries. Ann Rheum Dis. 2026. PMID: 42697827. doi:10.1016/j.ard.2026.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。